Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Trial Details

NCT ID
NCT06506838
Phase
PHASE4
Sponsor
Guangdong Provincial People's Hospital
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Anlotinib
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Age 18-75 years.
  • ECOG Performance Status score of 0-1.
  • Histologically or cytologically confirmed diagnosis of high-grade soft tissue sarcoma (G2-G3), classified as moderately sensitive or higher to chem…
  • Clinical confirmation of soft tissue sarcoma suitable for surgical resection after multidisciplinary assessment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →